Under Armour Revenue Slides 7% as Company Targets 50% SKU Reduction

What happened

Under Armour's second-quarter revenue declined 7% year-over-year to $1.2 billion, extending a streak of top-line contraction as the company struggles to regain demand, particularly in North America. The company announced a target of reducing product SKUs by 50%, a bold operational move aimed at simplifying the assortment, lowering inventory complexity, and potentially improving gross margins through reduced markdowns. This follows a period of heavy restructuring and elevated promotional pressure, with inventory at $1.075 billion as of December 2025 and gross margin under strain from tariffs (~$80 million impact) and discounting. While SKU rationalization may streamline operations and focus resources on core products, the immediate revenue decline suggests the brand is still not stabilizing, and execution risk remains high. The news does not provide profitability or balance sheet updates, so the fundamental turnaround thesis remains unproven, and investors should monitor whether the SKU cuts lead to improved sell-through without further revenue deterioration.

Implication

Investors should interpret the 7% revenue decline as evidence that demand weakness persists, particularly in the core North America market where previous quarters showed double-digit declines. The 50% SKU reduction is a significant strategic shift that could improve inventory efficiency and gross margins over time, but it carries execution risk, including potential loss of sales if popular products are eliminated or retail partners resist the narrowed assortment. Near-term, the absence of profitability guidance in the news means the cost structure remains unvalidated, and tariff headwinds may continue to pressure margins beyond the previously quantified fiscal 2026 impact. The original WAIT rating hinged on observing an SG&A step-down and improvement in North America revenue trends, neither of which has been clearly demonstrated by this update; the SKU plan is a leading indicator but not a proof point. Until there is consistent evidence of revenue stabilization and margin recovery, the stock is likely to remain range-bound with downside risk if the SKU reduction leads to lost sales without offsetting cost savings.

Thesis delta

The core WAIT thesis is unchanged: the company must still demonstrate that cost reductions can coexist with demand stabilization. The new SKU reduction plan introduces a potential catalyst for longer-term margin improvement, but it also adds execution risk that was not previously priced in. Until we observe the impact on sell-through and gross margin in subsequent quarters, the thesis holds with no upgrade.